All lobbying filings

THE MCMANUS GROUP

THE MCMANUS GROUP filed a Q4 report for ZIMMER BIOMET on January 20, 2026, reporting $50,000 in lobbying income.

Lobbying for ZIMMER BIOMET · A global leader in musculoskeletal healthcare.

All filings by THE MCMANUS GROUP · Everything ZIMMER BIOMET has reported

Filing · LD-2 quarterly report Q4 report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

Indiana

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Medicare/Medicaid

Access and reimbursement of medical devices in Medicare program. Issues related to capping beneficiary copayments for Medicare beneficiaries in ambulatory surgery centers, included in Medicare Beneficiary Co-Pay Fairness Act of 2025(H.R. 3006/S. 1776) The Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 5343/S. 1717)

Health Issues

Issues related to Artificial Intelligences approval in Medical Devices.

Bills named in this filing 4

H.R. 3006
To amend title XVIII of the Social Security Act to limit the coinsurance amount for certain services furnished in an am…
S. 1776
Medicare Beneficiary Co-Pay Fairness Act
H.R. 5343
Ensuring Patient Access to Critical Breakthrough Products Act
S. 1717
Ensuring Patient Access to Critical Breakthrough Products Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.